πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

1,328 results for β€œChina” Clear

  1. ASC47

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Weight Management

    phase 1 small molecule completed

    1 trial

  2. Abatacept

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Dermatomyositis

    phase 1 small molecule active

    1 trial

  3. Allogeneic CD19/BCMA-targeted CAR-Ξ³Ξ΄T cell injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory/Relapsed Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

  4. Anti-CD19 Universal CAR-T Cells injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  5. Anti-CD30 CAR T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Adult T-Cell Lymphoma/Leukaemia

    phase 1 gene therapy active

    1 trial

  6. Anti-CDH17 CAR-T cells infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CDH17-positive Advanced Solid Tumors

    phase 1 mab active

    1 trial

  7. Anti-CLL1 CART cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  8. Autologous differentiated myocyte transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metabolic Disease

    phase 1 mab active

    1 trial

  9. Autologous tumor-infiltrating lymphocyte cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumor

    phase 1 mab terminated

    1 trial

  10. Autologous Ξ³Ξ΄T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Hodgkin's Lymphoma

    phase 1 mab active

    1 trial

  11. BC006

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumors (Including GCTTS)

    phase 1 small molecule active

    1 trial

  12. BZ019

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Large B-cell Lymphoma

    phase 1 mab active

    1 trial

  13. CAR T cells chimeric antigenreceptor cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  14. CAR-T cells chimenric antigen receptor T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  15. CAR-T cells chimeric antigen receptor T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Acute Myeloid Leukemia(AML)

    phase 1 small molecule active

    1 trial

  16. CD-001

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  17. CD123+CLL-1 dual-target CAR-T cells sequential infusion CD7 CAR-T cells and bridging to allogeneic

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML - Acute Myeloid Leukemia

    phase 1 mab active

    1 trial

  18. CD19-CD22 CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

    phase 1 mab terminated

    1 trial

  19. CD19-STAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B Cell Malignancy

    phase 1 mab completed

    1 trial

  20. CD19/BCMA in vivo CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Autoimmune Diseases

    phase 1 small molecule active

    1 trial

  21. CD19/CD20 Dual-CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Non-Hodgkin's Lymphoma

    phase 1 mab on hold

    1 trial

  22. CD19/CD20 Dual-CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Leukemia

    phase 1 mab completed

    1 trial

  23. CD7 UCAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-cell Leukemia

    phase 1 mab active

    1 trial

  24. CLL1 and CD38 Dual-Target CAR-T Cell Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources